Sun Yat-sen University

This Phase 3 trial is testing whether a lower dose of radiation, combined with chemotherapy and immunotherapy, can control stage III nasopharyngeal cancer as well as the standard higher dose. About 593 participants whose tumors respond well to initial treatment will be randomly a…

This phase 2 trial tests whether combining dalpiciclib (a CDK4/6 inhibitor) with camrelizumab (an immunotherapy) can shrink tumors in 30 people with advanced liver cancer that progressed after prior immunotherapy. The study aims to find a new second-line option for this hard-to-t…

This Phase 2 trial is testing whether adding the drug dalpiciclib to standard anti-HER2 and hormone therapy can help keep advanced breast cancer from growing. It involves 57 women with HR+/HER2+ metastatic breast cancer whose disease has not worsened after initial treatment. The …

This study tests whether adding an immunotherapy drug (penpulimab) to standard chemotherapy and radiation, followed by maintenance immunotherapy, works better than the usual maintenance drug capecitabine for people with high-risk nasopharyngeal cancer. About 142 participants with…

This study tests a combination of three drugs—pucotenlimab (an immunotherapy), lenvatinib (a targeted therapy), and irinotecan (chemotherapy)—in 24 children aged 2-18 with advanced or relapsed hepatoblastoma that has not responded to prior treatment. The goal is to see if this mi…

This phase II trial is testing whether removing the usual safety margin around the tumor during online adaptive stereotactic body radiotherapy (SBRT) can lower breathing-related side effects while still controlling early-stage non-small cell lung cancer or limited lung metastases…

This phase 3 trial tests whether adding a precise form of radiation (SBRT) to the immunotherapy drug camrelizumab helps control cancer better than camrelizumab alone in people with nasopharyngeal cancer that has spread to a few spots (oligometastatic). About 188 adults whose prim…

This phase 3 trial is testing whether giving a lower dose of radiation to low-risk areas around the main tumor works as well as the standard higher dose for nasopharyngeal cancer. The study plans to enroll 700 people aged 18-70 with newly diagnosed, non-spreading cancer. The goal…

This early-stage trial tests a custom-made vaccine (SarcVac) designed from each patient's tumor mutations, combined with immune-boosting cells and a PD-1 antibody. It enrolls 16 adults with advanced bone or soft tissue sarcoma that did not respond to first-line treatment. The mai…

This phase 3 trial tests whether adding two drugs—toripalimab and capecitabine—after standard chemoradiation can prevent esophageal cancer from coming back. About 242 adults with advanced esophageal cancer who finished chemoradiation without progression will be enrolled. The goal…

This phase 2 trial is testing whether giving the immunotherapy drug toripalimab, alone or with the anti-inflammatory drug celecoxib, before surgery can improve outcomes for people with a specific type of colorectal cancer (dMMR/MSI-H). About 270 participants will receive the trea…

This study tests whether a shorter course of radiation (hypofractionated) combined with chemotherapy and immunotherapy works better than the standard longer radiation schedule for people with advanced esophageal cancer that cannot be removed by surgery. About 134 participants wil…

This phase II trial is testing whether a new combination of drugs (cetuximab, envafolimab, and a stronger chemo mix) works better than the current standard treatment for people with a specific type of advanced colorectal cancer that has spread. The study will enroll 198 participa…

This phase II trial is testing whether combining two types of radiation (SBRT and low-dose radiation) with an immunotherapy drug (toripalimab) and chemotherapy can help control recurrent or metastatic nasopharyngeal carcinoma. The study will enroll 148 participants who have not r…

This early-phase study is testing an experimental drug called WTX212A, given alone or after radiation therapy, in 12 people with advanced solid tumors. The main goal is to see if the drug is safe and whether it can shrink tumors. Because this is a phase 1 trial, it is very small …

This phase II trial tests whether giving chemotherapy directly into the liver artery plus an immunotherapy drug (tislelizumab) before surgery, followed by more immunotherapy after surgery, can prevent liver cancer from returning in high-risk patients. The study enrolls 39 adults …

This Phase 2 trial tests whether adding thymosin alpha 1 to the immunotherapy drug toripalimab can help elderly patients (60+) with advanced melanoma. The study will enroll 55 participants and measure how many patients' tumors shrink or disappear. Researchers also want to see if …

This phase 2 trial is testing whether giving two drugs—sintilimab (an immunotherapy) and bevacizumab (a targeted therapy)—before surgery can help prevent liver cancer from coming back. The study includes 37 adults with resectable liver cancer that is beyond the Milan criteria, me…

This Phase II trial tests a targeted drug called trastuzumab rezetecan, alone or with an immunotherapy called adebrelimab, in people with advanced bladder cancer that has a specific protein (HER2). The study aims to see if these treatments can shrink tumors or slow cancer growth.…

This phase 2 trial is testing whether giving a combination of chemotherapy (paclitaxel polymersomes and carboplatin) plus an immunotherapy drug (adebelimab) before surgery can help shrink tumors in people with resectable mucosal melanoma. About 32 participants will receive up to …

This study tests two ways to treat lung cancer that has spread to the brain. One group gets focused radiation plus a drug called bevacizumab; the other gets whole-brain radiation that tries to protect memory areas. The goal is to see which approach better controls brain tumors an…

This study tests a new way to give an immunotherapy drug (adebrelimab) for advanced liver cancer that has spread. About 76 people will get the drug either directly into the liver artery or through a vein, along with standard chemotherapy and another targeted drug. The goal is to …

This study tests a new approach for people with a common type of locally advanced rectal cancer. It combines low-dose radiation with an immunotherapy drug (pucotenlimab) and chemotherapy before surgery. The goal is to see if this combination can make the tumor disappear completel…

This early-phase study tests a new treatment called IX001 TCR-T for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. The…

This phase 3 trial tests whether adding an immunotherapy drug (pucotenlimab) to standard chemotherapy (CAPOX) improves outcomes for people with locally advanced rectal cancer. About 556 adults aged 18-75 will be randomly assigned to receive either the new combination or chemother…

This trial tests a new drug called Cadonilimab in 28 people with advanced colorectal cancer that has a specific genetic feature (MSI-H or dMMR) and has stopped responding to standard immunotherapy. The drug targets two immune checkpoints (PD-1 and CTLA-4) at once, aiming to shrin…

This phase 2 trial is testing whether a combination of two immunotherapy drugs (QL1706) and a targeted therapy (lenvatinib) can shrink kidney tumors before surgery. The goal is to make partial nephrectomy (removing only the tumor) possible for patients whose tumors are currently …

This phase 3 trial tests whether adding an immunotherapy drug (cadonilimab) and low-dose radiation to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 380 participants will be randomly assigned to receive either the new combination …

This phase 2 trial tests whether adding the immunotherapy drug penpulimab to standard AVD chemotherapy improves outcomes for people with newly-diagnosed advanced classic Hodgkin lymphoma. About 108 adults will receive either concurrent or sequential treatment. The main goal is to…

This phase II trial is testing whether adding the immunotherapy drug Toripalimab to different platinum-based chemotherapy regimens, followed by standard chemoradiotherapy, can improve outcomes for people with locally advanced nasopharyngeal cancer. About 243 participants will be …

This phase 2 trial is testing whether adding low-dose radiotherapy to a standard chemotherapy regimen plus the immunotherapy drug toripalimab can help people with recurrent or metastatic nasopharyngeal carcinoma. About 55 participants will receive the combination therapy in cycle…

This phase 2 trial tests a combination of three drugs—chidamide, sintilimab, and bevacizumab—in 34 people with advanced extrapulmonary neuroendocrine carcinoma that has worsened after first-line therapy. The goal is to see if this combo can shrink tumors or slow disease progressi…

This phase 3 trial tests whether a structured nutrition plan (including supplements, feeding tubes, or IV nutrition) helps malnourished patients with advanced nasopharyngeal carcinoma maintain weight and improve their outlook. About 266 participants will be randomly assigned to s…

This phase 2 trial is testing whether a fasting-mimicking diet (a low-calorie, plant-based diet) can improve the effectiveness of standard chemoimmunotherapy for early or locally advanced triple-negative breast cancer. About 80 women aged 18 to 70 will follow the diet for five da…

This study is for people whose nasopharyngeal cancer has come back after initial treatment and cannot be removed by surgery. Participants first receive a combination of chemotherapy and an immunotherapy drug (PD-1 inhibitor). Those whose tumors shrink or disappear are then random…

This study looks at men whose prostate cancer has spread to nearby lymph nodes after prostate removal surgery. It compares two treatments: hormone therapy alone versus hormone therapy plus radiation to the pelvis. The goal is to see if adding radiation delays the cancer from comi…

This study tests two drugs, toripalimab and celecoxib, in people with a specific type of colorectal cancer (dMMR or MSI-H) that has not spread far. The goal is to see if the treatment can make the tumor disappear completely, so some patients might not need surgery. About 105 adul…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (CAV/IE) helps people with advanced bone or soft tissue sarcoma that hasn't responded to previous treatments. About 134 participants will be randomly assigned to get either the combo or ch…

This study is for people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. It compares two second-line approaches: adding lenvatinib to the original regimen or switching to regorafenib plus a PD-1 inhibitor. The goal is to see which c…

This study tests whether adding two drugs, toripalimab and surufatinib, to standard chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without the disease getting worse. About 47 adults aged 18 to 75 with stage I to III small cell lung cancer …

This study tests if cooling the kidney with ice slush during robot-assisted partial nephrectomy helps the kidney recover from the temporary lack of blood flow. About 310 adults with kidney cancer will take part. The goal is to see if cold ischemia improves kidney function after s…

This study tests a combination of three drugs—an EGFR antibody, a PD-1 inhibitor, and chemotherapy—in people whose nasopharyngeal cancer has returned or spread. The goal is to see if this mix can slow or stop the cancer from growing. About 148 adults aged 18-75 who have not had p…

This study tests a drug called toripalimab, which helps the immune system fight cancer. It is for people with advanced solid tumors that have specific gene changes (POLE or POLD-1) and are not helped by standard treatments. The goal is to see if the drug can shrink tumors or slow…

This study tests whether using special MRI scans to guide radiation therapy can reduce lung damage and improve outcomes for people with advanced non-small cell lung cancer. About 490 adults with stage III lung cancer will receive radiation, chemotherapy, and immunotherapy. Half w…

This study tests whether combining the drug golidocitinib with either mitoxantrone liposome or chidamide can safely shrink tumors in people with peripheral T-cell lymphoma that has returned or not responded to prior therapy. About 101 adults will receive one of the combinations. …

This study tests a combination of two drugs, eribulin and anlotinib, in 52 women with HER2-negative advanced breast cancer whose disease has worsened after prior treatments like antibody-drug conjugates. The goal is to see if the combo can slow cancer growth and improve survival.…

This study tests whether adding an immunotherapy drug (anti-PD-1 antibody) to standard chemoradiotherapy helps people with nasopharyngeal cancer that has come back after initial treatment. About 212 adults whose cancer cannot be removed by surgery will be randomly assigned to rec…

This study tests whether a blood test that detects tiny bits of tumor DNA can help doctors decide who needs extra immunotherapy (toripalimab) after lung cancer surgery. About 80 adults with stage IB-IIIA non-small-cell lung cancer will receive treatment based on their blood test …

This study looks at whether early heart monitoring and treatment can help people with advanced lung cancer who are receiving strong cancer therapies. About 524 adults with stage III non-small cell lung cancer will be enrolled. The goal is to see if this approach improves survival…

This study compares two modern surgical methods for treating low rectal cancer: transanal total mesorectal excision (taTME) and robot-assisted surgery (RTME). The goal is to see which approach leads to fewer complications and better recovery. About 216 adults with newly diagnosed…

This study tests a drug called becotatug vedotin in people with advanced nasopharyngeal cancer whose tumors didn't shrink enough after standard chemo-immunotherapy. About 59 adults will receive the drug during and after radiation therapy. The goal is to see if this approach can p…

This phase 3 trial aims to see if adding chemotherapy (cisplatin) to standard radiation therapy after surgery helps people with intermediate-risk head and neck squamous cell carcinoma live longer without the cancer returning. About 386 participants who have had surgery and show c…

This study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely avoid low-dose radiation to the neck afterward. The goal is to maintain cancer control while reducing side effects and improving quality …

This study tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy before surgery can help people with a certain type of esophageal cancer. The goal is to make the tumor easier to remove completely, lower the chance of cancer coming back, and improve surv…

This study is for people with nasopharyngeal cancer that has spread to other parts of the body. Researchers want to see if waiting to give radiation to the head and neck area (only if needed later) works as well as giving it right away, after initial treatment with a PD-1 inhibit…

This study tests a combination of two drugs (Sac-TMT and Tagitanlimab) in 35 people with a specific type of advanced breast cancer that is hormone receptor-positive, HER2-negative, and PD-L1-positive. Participants must have already been treated with a CDK4/6 inhibitor. The goal i…

This study tests whether adding the drug selinexor to standard chemotherapy (R-CHOP) can improve outcomes for people with a specific, hard-to-treat type of lymphoma (TP53-mutated DLBCL) who have not had prior treatment. About 42 adults aged 18-80 will receive the combination, fol…

This study tests a new combination of drugs and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The treatment includes surufatinib, immunotherapy, chemotherapy, and radiation. The goal is to see if this approach can stop the cancer from gro…

This study tests two different chemotherapy combinations for people with metastatic colorectal cancer that has spread and needs a second treatment. About 280 adults will be randomly assigned to receive either FOLFIRI or irinotecan, with or without bevacizumab. The goal is to see …

This study tests a new drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery or has spread. Participants receive the drug every 3 weeks. The main goal is to see if the cancer stays stable for at least 12 weeks. Researchers wil…

This phase 3 trial tests whether adding immunotherapy to standard treatment can improve outcomes for people with advanced nasopharyngeal cancer. About 802 participants will be split into low-risk and high-risk groups to see if personalized treatment can reduce side effects and pr…

This study tests a new combination of drugs (iparomlimab, tuvonralimab, chemotherapy, and lenvatinib) as a second-line treatment for people with advanced bile duct cancer that has worsened after first-line therapy. The goal is to see if this approach can help control the cancer a…

This study is for people with advanced triple-negative breast cancer that cannot be removed by surgery. It tests different ways of combining radiation therapy with immunotherapy to see which works best to control the cancer. The goal is to keep the cancer from growing for as long…

This study tests whether adding a short course of radiation to a mix of immunotherapy (iparomlimab and tuvonralimab), a targeted drug (regorafenib), and chemotherapy (CAPOX) can better shrink advanced rectal cancer before surgery. About 88 adults with a specific type of rectal ca…

This study tests whether giving targeted drugs before surgery can help people with stage III lung cancer that has rare gene changes. About 120 adults who have not had treatment will receive a drug matched to their tumor's mutation, then doctors will check if the tumor becomes rem…

This study tests whether freezing tumors (cryoablation) combined with an immunotherapy drug (camrelizumab) can shrink advanced soft tissue sarcomas that have stopped responding to standard treatments. About 57 participants aged 14 to 70 will receive this combination. The main goa…

This study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy can help people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. About 84 newly diagnosed patients will be randomly assigned to receive either the combinati…

This study tests whether a combination of two experimental drugs (iparomlimab and tuvonralimab) plus standard chemotherapy and a targeted therapy can shrink tumors in adults with a specific type of advanced colorectal cancer (BRAF V600E mutation). About 20 people whose cancer has…

This study tests whether giving a combination of drugs (IBI308, bevacizumab, pemetrexed, and carboplatin) before surgery can shrink stage III non-small cell lung cancer enough to allow surgical removal. The goal is to see how many people can then have surgery. The study includes …

This study tests whether removing extra safety margins during MRI-guided radiation can safely treat lung cancer that has spread to the brain. About 168 adults with 1 to 10 brain metastases will receive precise, adaptive radiation without the usual buffer zone. The goal is to redu…

This study tests a new way of giving chemotherapy called adaptive therapy for people with advanced breast cancer that has gotten worse after standard treatments. The goal is to see if adjusting the dose over time can help control the cancer longer and with fewer side effects. Abo…

This study compares two types of minimally invasive lung surgery for people with early-stage non-small cell lung cancer: robot-assisted surgery (RATS) and video-assisted surgery (VATS). About 1,124 participants will be randomly assigned to one of the two procedures. The main goal…

This phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and cannot be surgically removed wi…

This study compares two chemotherapy combinations in 88 children (ages 6 months to 18 years) whose rhabdomyosarcoma has returned or not responded to prior treatment. One group receives doxorubicin liposome plus irinotecan (AI regimen), the other receives the standard VIT regimen.…

This study is for people with kidney cancer that has spread to up to 5 places in the body. It tests whether adding precise, high-dose radiation (SBRT) to standard drug therapy (targeted agents and immunotherapy) helps them live longer without the cancer growing. About 252 adults …

This study tests a new combination of chemotherapy drugs for children and teens with hepatoblastoma, a rare liver cancer. The goal is to improve survival, especially for high-risk patients who currently have poor outcomes. About 100 participants under 18 will receive the treatmen…

This study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus a targeted antibody (nimotuzumab) in people with advanced nasopharyngeal cancer that got worse after standard first treatment. About 41 adults aged 18-70 will receive the therapy to se…

This study tests whether giving two drugs (pucotenlimab and vorolanib) before surgery can shrink kidney tumors enough to allow partial kidney removal instead of full removal. It includes 21 adults with high-risk clear cell renal cancer who need surgery but have tumors that make k…

This study tests whether adding two liver-directed treatments (chemoembolization and artery infusion) to standard immunotherapy can shrink tumors better in people with advanced liver cancer that cannot be removed by surgery. About 55 adults with good liver function and performanc…

This study tests whether combining zanubrutinib (a targeted pill) with rituximab (an antibody infusion) can shrink or control MALT lymphoma, a slow-growing cancer of the lymph nodes and organs. About 42 adults with newly diagnosed advanced disease or lymphoma that returned after …

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation before surgery helps people with a certain type of esophageal cancer live longer. About 422 adults with stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal cancer who…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…

This study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery can help eliminate more cancer cells in women with early-stage triple-negative breast cancer. About 192 participants will receive either standard treatment alone or standard trea…

This study tests a strategy to avoid removing the entire rectum in certain low rectal cancer patients who have had radiation. During surgery, a piece of the tumor is checked immediately under a microscope. If the cancer is only in the surface layer, the surgery stops and the pati…

This study tests two different chemotherapy combinations for people with extensive stage small cell lung cancer, a type that has spread widely. The goal is to see which combo works better at stopping the cancer from growing. About 90 adults who haven't had prior treatment for thi…

This study tests a combination of three drugs (surufatinib, sintilimab, and capecitabine) in people with advanced small bowel or appendix cancer that has spread and stopped responding to standard treatments. The goal is to see if this mix can shrink tumors or slow cancer growth. …

This study compares a newer, low-temperature plasma ablation method with standard high-frequency electrocautery surgery for people whose nasopharyngeal cancer has come back after initial treatment. About 500 participants will be randomly assigned to one of the two procedures. The…

This study tests a combination of two drugs (orelabrutinib and rituximab) followed by maintenance orelabrutinib in 32 adults with relapsed or refractory follicular lymphoma. The goal is to see how well the treatment shrinks tumors and how long it keeps the cancer under control. P…

This study tests two drugs, QL1706 and lenvatinib, in people with advanced penile cancer that has already been treated. The goal is to shrink tumors and possibly make them removable by surgery. About 47 adults aged 18–80 will receive the drugs for up to a year, with the aim of co…

This study tests a new drug combination (FOLFOX chemotherapy plus atezolizumab and bevacizumab) for people with advanced liver cancer whose disease got worse after initial treatment with atezolizumab and bevacizumab. About 30 adults with advanced liver cancer will receive this se…

This study tests whether adding two drugs (serplulimab and bevacizumab) to standard chemotherapy improves outcomes for people with colorectal cancer that has spread to the liver and can be surgically removed. The trial involves 156 adults aged 18-75 with specific genetic types (R…

This study is for people with a type of advanced lung cancer that cannot be removed by surgery. It tests a new approach that combines chemotherapy, radiation, and two types of immunotherapy to see if it can control the cancer longer. The trial involves 56 participants and aims to…

This study tests a new two-pronged approach for people with B-cell lymphoma that has come back or not responded to standard treatments. It combines a personalized cell therapy (relmacabtagene autoleucel, a type of CAR-T) with an immunotherapy drug (sintilimab) to try to boost the…

This study tests a drug called apatinib combined with two chemotherapy drugs (irinotecan and temozolomide) in children aged 5 to 18 with neuroblastoma that has returned or not improved after standard treatment. The goal is to see if the combination can shrink tumors and help chil…

This study tests whether adding prostate cryoablation (freezing the tumor) and a low-dose chemotherapy drug (cyclophosphamide) to standard hormone therapy can delay cancer progression in men with newly diagnosed metastatic prostate cancer. About 104 men aged 18-80 will receive th…

This study is testing a new imaging technique called photoacoustic tomography (PACT) to see blood vessels and oxygen levels in the feet without using dyes or needles. The goal is to help doctors diagnose lower extremity artery disease (LEAD) more accurately and earlier. Researche…

This study is testing a new tool that uses DNA methylation patterns to figure out where a cancer started when doctors can't find the original tumor. Researchers will analyze tissue samples from 120 people with cancer of unknown primary. If it works, this approach could help guide…

This study tests whether inhaling a drug called penehyclidine hydrochloride before surgery can prevent breathing complications in children aged 3 to 7 who are at higher risk. The trial involves 204 kids undergoing minor eye surgery with sevoflurane anesthesia. Researchers will co…

This study tests if rinsing the rectum with fluid during keyhole surgery can lower the chance of rectal cancer returning. About 1,600 adults with mid-to-low rectal cancer will be randomly assigned to receive the wash or not. Researchers will track cancer recurrence, survival, and…

This phase 3 trial tests whether Houyanqing Oral Liquid, a Chinese herbal mix, can prevent or reduce severe mouth sores caused by radiation therapy in 386 nasopharyngeal cancer patients. Participants take the liquid four times daily during radiation, alongside standard care. The …

This study tests whether Xinlikang capsules can reduce severe fatigue and improve immune health in people with diffuse large B-cell lymphoma who have finished chemotherapy and are in remission. About 80 participants will receive either the capsule or a placebo. The goal is to see…

This study tests whether giving radiation only to the specific neck areas where cancer has spread can reduce side effects and improve quality of life for people with nasopharyngeal carcinoma, without affecting survival. About 470 newly diagnosed patients will be assigned to eithe…

This observational study tracks 800 people with metastatic breast cancer to see if differences in HER2 levels across tumors affect how well trastuzumab deruxtecan works. Researchers will compare progression-free and overall survival based on HER2 patterns. The goal is to better u…

This study aims to improve early detection of liver cancer in people with hepatitis B-related liver cirrhosis. Researchers will use artificial intelligence to analyze health data from 6,000 participants and track who develops cancer. The goal is to create a better risk assessment…

This study tests whether an AI-powered teaching agent can help medical graduate students learn machine learning and data mining more effectively. About 56 students will use the AI tool for real-time help, study planning, and project guidance. Their performance will be compared to…

This study follows 30,000 people diagnosed with coronary artery disease over many years. Researchers will track which patients die and why, looking at known and suspected risk factors. The goal is to better understand what influences long-term survival in real-world heart disease…

This study tests whether a 4-week online program can help parents better support healthy behaviors in their preschool children (ages 3-6). The program covers physical activity, reducing screen time, handwashing, and cutting down sugary drinks. Researchers will compare parents who…

This study looks at two different methods (one-needle vs two-needle) for placing a PICC line, a long-term IV used for treatments like chemotherapy. About 284 adults who need a PICC for the first time will take part. The goal is to find out which method leads to fewer complication…

This study looks at whether checking for pieces of tumor DNA in the blood (called ctDNA) can help doctors see how well treatment is working and find cancer returning early in children with neuroblastoma. About 200 children with newly diagnosed or returning neuroblastoma will give…

This study follows 2000 adults with at least moderate mitral regurgitation (a leaky heart valve) to identify factors that raise the risk of death or heart failure hospitalization. Researchers will use echocardiograms and other data to build a model that helps doctors decide on th…

This study reviews medical records of 446 people with hepatitis B-related liver failure who received stem cell therapy. Researchers want to find out why some patients did not improve. The goal is to identify factors that affect treatment success so future patients can benefit mor…

This study follows 2000 people with IgA nephropathy who still have good kidney function. Researchers will test blood and urine samples to find biomarkers that might predict if and when kidney disease gets worse. The goal is to better understand the disease, not to test a new trea…

This study looks at 50 people with nasopharyngeal cancer that has come back or spread. Researchers will use advanced lab tests (multi-omics) to see if they can predict how well a combination of chemotherapy, radiation, and immunotherapy works. The goal is to find better ways to p…

This study looks at two ways to place a thin, flexible tube (called a PICC) in cancer patients who need long-term IV treatments. One method uses magnetic tracking, and the other uses heart signals (ECG) to guide the tube to the right spot. Researchers want to see which method wor…

This study is following 4,000 adults diagnosed with heart valve disease to discover new risk factors and understand how certain natural chemicals (metabolites) in the body influence the disease. Researchers will track participants over time and test tissue samples. The goal is to…